Other · developed by BioNTech
BNT3219 is an investigational agent given by intravenous infusion.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07893054 | Phase 1 | Advanced Solid Tumors | Not yet recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →